Comparative Laboratory Performance Evaluation of Pillar Biosciences, ArcherDx, and ThermoFisher Sequencing Chemistries for the Targeted Characterization of CRC & NSCLC Samples
Pillar Biosciences oncoRevealTM methylQuant Panels: Accurate and easy-to-use methylation NGS assays leveraging SLIMamp technology

Pillar developed two research-use bisulfite NGS methylation panels on SLIMamp® chemistry — one covering BRCA1, RAD51C, BRCA2 and XRCC3, the other MGMT and MLH1 — aimed at the high DNA input, informatics burden and readout accuracy problems that have slowed methylation testing in solid tumors. Primers bind bisulfite-converted methylated and unmethylated DNA equally but not unconverted genomic DNA, and the protocol is two rounds of PCR with purification. Across Zymo standards, moderately and severely formalin-compromised Horizon DNA and CAP FFPE samples, observed methylation matched expected levels with Pearson’s r above 0.99 at 5–20 ng input.
Combining High-Throughput, High-Resolution Targeted Spatial Microdissection with SLIMamp® NGS Chemistry for Sensitive and Accurate Molecular Characterization on Low-Quantity, Low-Quality FFPE Samples

Pillar, QuantumCyte and AstraZeneca tested whether AI-guided spatial microdissection can rescue FFPE samples that would otherwise fail NGS. QuantumCyte’s QCPRECISE!™ platform uses digital pathology to annotate slides and a printed mask to remove unwanted regions, extracting DNA from selectively lysed tumor cells in 2 mm tissue microarray cores taken from 31 samples previously characterized on Pillar’s oncoReveal® HRD and BRCA1 & RAD51C methylation panels. Libraries were sequenced on the NextSeq 550 and analyzed in PiVAT®. Variants were called on all 31 samples with no cross-contamination, and 76% of evaluable samples matched known variant allele frequencies at 0.93 correlation.
Evaluation of Homologous Repair Deficiency Status in Ovarian Carcinoma using In House Next Generation Sequencing Panels

Temple University Hospital evaluated Pillar’s oncoReveal® HRDv2 assay together with the oncoReveal® methylation assay for assessing homologous recombination deficiency (HRD) in ovarian carcinoma, the marker predicting PARP inhibitor benefit in tubo-ovarian high-grade serous carcinoma. Thirty-one retrospective FFPE ovarian specimens — 20 high-grade serous, 4 clear cell, 3 mucinous, 3 endometrioid and 1 mixed — were microdissected and run for SNVs, indels and exon-level copy number variants across 33 genes on the Illumina MiSeq, plus BRCA1, BRCA2, RAD51C and XRCC3 promoter methylation, with PiVAT® analysis. Pathogenic HRD mutations appeared in 28 of 31 specimens (90%), and methylation identified further HRD-positive cases.
Minimizing Sample Failure Rates for Challenging Clinical Tumor Samples
Publication Source: The Journal of Molecular Diagnostics
TBC
Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?
Publication Source: American Society of Clinical Oncology
TBC
Quality metrics for enhanced performance of an NGS panel using single-vial amplification technology
Publication Source: Journal of Clinical Pathology
TBC
Localizing next-generation sequencing testing for cancer patients: How to help clinicians optimize selection of precision therapies via integration of NGS testing into local pathology labs.
Publication Source: Drug Discovery & Development
TBC
Abnormal TP53 Predicts Risk of Progression in Patients with Barrett’s Esophagus Regardless of a Diagnosis of Dysplasia
Publication Source: Gastroenterology
TBC